In Vivo Inhibition of Acute Platelet-Dependent Thrombosis in a Baboon Model by BAY U3405, a Thromboxane A₂-Receptor Antagonist

Summary

Bay U3405 is a thromboxane A₂ (TxA₂)-receptor antagonist that inhibits the binding of TxA₂ to its target cells. The aim of this study was to determine if Bay U3405 could be used to inhibit arterial thrombosis. A thrombogenic de vice, consisting of uncrimped Dacron vascular graft material (0.5 cm²) built into the wall of silicone rubber tubing with 4 mm inside diameter, was exposed to native flowing blood under arterial blood flow conditions (100-140 ml/min) by interposing the devices as extension segments into permanent femoral arteriovenous shunts implanted in baboons. Thrombus formation was quantified in vivo by measuring the deposition of ¹¹¹In-labelled platelets onto the graft material with a scintillation camera. In six baboons, a bolus injection of Bay U3405, calculated to attain an initial plasma concentration of 300 ng/ml, reduced the maximum thrombus formation measured over a 2 h study period. Platelet deposition was reduced by 33 ± 14% (SD) at 2 h as compared to control studies done in the same baboons. The accumulation of additional platelets onto a thrombus that was allowed to form for 1 h, was reduced by 58 ± 28% at 2 h. Ex vivo platelet aggregation in response to ADP, activated partial thromboplastin time (APTT), prothrombin time (PT), and thrombin time (TT) were not affected by the treatment. Ex vivo platelet aggregation in response to collagen was markedly inhibited for 2 h after treatment. The results demonstrated that selective blocking of the TxA₂-receptor on platelets reduced platelet-dependent thrombus formation and the accumulation of additional platelets in a freshly formed thrombus. This may provide a viable approach for preventing excessive thrombus formation in patients undergoing arterial reconstructive surgery.

• References

• 1 Ogletree ML. Overview of physiological and pathophysiological effects of thromboxane A₂ . Fed Proc 1987; 46: 133-138
• 2 Smith BJ. Pharmacology of thromboxane synthetase inhibitors. Fed Proc 1987; 46: 139-143
• 3 Lefer AM, Darius H. A pharmacological approach to thromboxane receptor antagonism. Fed Proc 1987; 46: 144-148
• 4 Perzbom E, Seuter F, Fiedler VB, Rosentreter U, Böshagen H. Action of novel selective thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido) 1,2,3,4-tetrahydro-9-carbazolepropanoic acid on vascular smooth muscle preparations. Arzneimittelforschung 1989; 39: 1522-1525
• 5 Seuter F, Perzbom E, Rosentreter U, Böshagen H, Fiedler VB. Inhibition of platelet aggregation in vitro and ex vivo by the new thromboxane antagonist (3R-3-(4-fluorophenylsulfonamido) 1,2,3,4-tetrahydro-9-carbazolepropanoic acid. Arzneimittelforschung 1989; 39: 1525-1527
• 6 Fiedler VB, Perzborn E, Seuter F, Rosentreter U, Böshagen H. Reduction of in vivo coronary artery thrombosis by the novel thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido) 1,2,3,4-tetrahydro-9-carbazolepropanoic acid. Arzneimittelforschung 1989; 39: 1527-1530
• 7 Fiedler VB, Perzhorn E, Seuter F. Protective effect of a novel thromboxane antagonist, Bay U3405, on canine myocardial damage after coronary occlusion and reperfusion. Pharmacotherapy 1991; 11: 77-84
• 8 Perzborn E, Seuter F. The action of Bay U3405, a specific thromboxane A₂ antagonist, in models of thromboembolism and sudden death. Thromb Haemostas 1991; 65: 1178 (Abstract)
• 9 Ma X-L, Karasawa A, Lefer AM. Mechanism of the protective action of Bay U3405, a new specific thromboxane receptor antagonist, in arachinodate-induced sudden death. Meth Find Exp Clin Pharmacol 1991; 13: 105-110
• 10 Escolar G, Garrido M, Albors M, Ordinas A. Effect of a thromboxane antagonist on platelet function and platelet-subendothelium interactions: influence of aspirin pretreatment. Thromb Haemostas 1991; 65: 1282 (Abstract)
• 11 Drouet L, Bai C, Pignaud G, Cissé-Thiam M. Comparative anti-thrombotic effects of aspirin and a thromboxane A₂ antagonist in vivo in the guinea pig. Thromb Haemostas 1991; 65: 1357 (Abstract)
• 12 Schneider PA, Kotzé HF, Heyns A, Hanson SR. Thromboembolic potential of synthetic vascular grafts in baboons. J Vase Surg 1989; 10: 75-82
• 13 Hanson SR, Kotzé HF, Savage B, Harker LA. Platelet interactions with Dacron vascular grafts. A model of acute thrombosis in baboons. Arteriosclerosis 1985; 05: 595-603
• 14 Savage B, McFadden PR, Hanson SR, Harker LA. The relation of platelet density to platelet age: Survival of low- and high density ¹¹¹Indium labelled platelets in baboons. Blood 1986; 68: 386-393
• 15 Kelly AB, Marzec UM, Krupski W, Bass A, Cadroy Y, Hanson SR, Harker LA. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons. Blood 1991; 77: 1006-1012
• 16 Kotzé HF, Lötter MG, Badenhorst PN, Heyns A. Kinetics of In-111-platelets in the baboon: 1. Isolation and labelling of a viable and representative platelet population. Thromb Haemostas 1985; 53: 404-407
• 17 Kotze HF, Heyns A, Lötter MG, Pieters H, Roodt JP, Sweetlove MA, Badenhorst PN. Comparison of oxine and tropolone methods for labelling platelets with indium-111. J Nucl Med 1991; 32: 62-66
• 18 Hanson SR, Harker LA. Studies on suloctidil in experimental thrombosis in baboons. Thromb Haemostas 1985; 53: 423-427
• 19 Hanson SR, Harker LA. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-argenyl chloromethylketone (FPRCH₂C1). Proc Natl Acad Sci, USA 1988; 85: 3184-3188
• 20 Van Wky V, Heyns A. Low molecular weight heparin as an anticoagulant for in vitro platelet function studies. Thromb Res 1990; 57: 601-609
• 21 Packham M. Platelet function inhibitors. Thromb Haemostas 1983; 50: 610-619
• 22 Hanson SR. Platelet-specific antibodies as in vivo therapeutic reagents: a baboon model. In Platelet Immunobiology: Molecular and Clinical Aspects. Kunicki TJ, George JN. (eds) JB Lippencott Company; Philadelphia, PA: 1989: 471-483
• 23 Hanson SR, Harker LA. Baboon models of acute arterial thrombosis. Thromb Haemostas 1987; 58: 801-805
• 24 Lane IF, Lumley P, Michael MF, Peters AM, McCollum CN. A specific thromboxane receptor inhibitor blocking drug, AH23848, reduces platelet deposition on vascular grafts in man. Thromb Haemostas 1990; 64: 369-373
• 25 Bech FR, Cronenwett JL, Mc Daniel MD, Ogletree ML, Freeman DH. The effect of thromboxane receptor blockade versus thromboxane synthase inhibition on canine arterial graft patency. J Vase Surg 1990; 12: 119-125
• 26 Armstrong RA, Jones RL, Wilson NH. Ligand binding to thromboxane receptors on human platelets: correlation with biological activity. Br J Pharmacol 1983; 82: 953-964
• 27 Kotzé HF, Lumsden A, Harker LA, Hanson SR. In vivo antithrombin effects of local versus systemic therapy with potent antithrombins. Circulation 1990; 82: 603 (Abstract)
• 28 Hanson SR, Kotzé HF, Harker LA, Scarborough RM, Charo IF, Phillips DR. Potent antithrombotic effects of novel peptide antagonists of platelet glycoprotein (Gp) IIb/IIIa. Thromb Haemostas 1991; 65: 813 (Abstract)